ArticleCardiology research2020
Model-Informed Development of Sotalol Loading and Dose Escalation Employing an Intravenous Infusion.
Article in Cardiology research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05247320 (Prospective Evaluation Analysis and Kinetics of IV Sotalol), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Prospective Evaluation Analysis and Kinetics of IV Sotalol
Who cites it
11 citing papers in PubMed, 19 citations in OpenAlex.
- Development and validation of a green dispersive liquid-liquid microextraction-LC-MS/MS method for sotalol quantification in human plasma using central composite design optimization and pharmacokinetic application.Scientific reports · 2026Article
- QT interval prolongation: clinical assessment, risk factors and quantitative pharmacological considerations.Journal of pharmacokinetics and pharmacodynamics · 2025Review
- Management of Arrhythmic Mitral Valve Prolapse: Potential Impact and Current Evidence.Reviews in cardiovascular medicine · 2025Review
- Population Pharmacokinetics and Pharmacodynamics of Sotalol Following Expedited Intravenous Loading in Patients With Atrial Arrhythmias.CPT: pharmacometrics & systems pharmacology · 2025Article
- Establishing an intravenous sotalol loading program.Heart rhythm O2 · 2025Review
- Safety and feasibility of intravenous sotalol loading for the prevention of ventricular arrhythmias.Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing · 2024Article
- Expedited loading with intravenous sotalol is safe and feasible-primary results of the Prospective Evaluation Analysis and Kinetics of IV Sotalol (PEAKS) Registry.Heart rhythm · 2024Observational
- Implementation of an intravenous sotalol initiation protocol: Implications for feasibility, safety, and length of stay.Journal of cardiovascular electrophysiology · 2023Article
- Protocol Development and Initial Experience With Intravenous Sotalol Loading for Atrial Arrhythmias.Critical pathways in cardiology · 2023Article
- Atrial Fibrillation Management: A Comprehensive Review with a Focus on Pharmacotherapy, Rate, and Rhythm Control Strategies.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2022Review
- Economics and outcomes of sotalol in-patient dosing approaches in patients with atrial fibrillation.Journal of cardiovascular electrophysiology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSotalol is often employed to prevent recurrence of symptomatic atrial flutter/atrial fibrillation. Because sotalol can prolong the QT interval excessively causing ventricular arrhythmias, a 3-day in-hospital loading or dose escalation period is mandated with oral administration in the product label for patient safety. In patients with normal renal function, 3 days (five oral doses) are required to obtain steady state maximum sotalol concentration, which results in maximum QT prolongation. The aim of this study is to develop an intravenous to oral loading regime for sotalol therapy that reduces the 3-day in-hospital initiation or dose escalation with oral administration to 1 day without compromising patient safety.
methodsUsing model-informed drug development techniques, simulations were developed for initiation and dose escalation of sotalol therapy by employing an intravenous loading dose followed by oral sotalol administrations.
resultsIn patients with normal renal function, an initial 1-h loading dose of intravenous sotalol followed by two oral doses in 24 h has been developed permitting attainment of three maximum serum concentrations reflecting maximum QT prolongation in a 1-day observation period. Dosing regimens for patients with impaired renal function are also developed.
conclusionsIn patients with normal renal function, using an intravenous loading dose followed by oral administrations permits safe initiation or dose escalation of sotalol in 1 day instead of the 3-day dosing regimen with oral administration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.